Lisanti Capital Growth LLC Trims Stock Holdings in SiBone $SIBN

Lisanti Capital Growth LLC cut its holdings in shares of SiBone (NASDAQ:SIBN) by 42.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,254 shares of the company’s stock after selling 43,291 shares during the quarter. Lisanti Capital Growth LLC owned approximately 0.14% of SiBone worth $872,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Peregrine Capital Management LLC acquired a new stake in shares of SiBone during the second quarter worth approximately $6,664,000. Next Century Growth Investors LLC bought a new position in SiBone during the 2nd quarter valued at $4,824,000. Assenagon Asset Management S.A. bought a new position in SiBone during the 3rd quarter valued at $3,297,000. Cubist Systematic Strategies LLC acquired a new position in SiBone during the 2nd quarter worth $4,079,000. Finally, BNP Paribas Financial Markets increased its position in shares of SiBone by 382.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 248,660 shares of the company’s stock worth $4,680,000 after purchasing an additional 197,092 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SiBone Stock Up 0.2%

Shares of SiBone stock opened at $16.58 on Friday. The stock has a market capitalization of $719.41 million, a price-to-earnings ratio of -32.51 and a beta of 0.69. SiBone has a twelve month low of $12.49 and a twelve month high of $21.89. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The business’s 50 day simple moving average is $18.94 and its 200-day simple moving average is $17.01.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The business had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. Equities research analysts forecast that SiBone will post -0.78 earnings per share for the current year.

Insider Buying and Selling at SiBone

In other SiBone news, SVP Michael A. Pisetsky sold 19,600 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $394,940.00. Following the sale, the senior vice president owned 231,896 shares in the company, valued at approximately $4,672,704.40. This trade represents a 7.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 18,542 shares of SiBone stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $373,621.30. Following the sale, the chief financial officer directly owned 185,231 shares in the company, valued at approximately $3,732,404.65. This trade represents a 9.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 207,886 shares of company stock valued at $3,996,367. Corporate insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SIBN. Canaccord Genuity Group increased their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. TD Cowen upgraded SiBone to a “strong-buy” rating in a research note on Tuesday. Needham & Company LLC increased their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Morgan Stanley boosted their price target on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SiBone presently has an average rating of “Moderate Buy” and an average target price of $24.33.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.